Combination therapy for a dopamine agonist
AssigneeAlto Neuroscience, Inc.
InventorsKathleen E. CLARENCE-SMITH, Thomas N. CHASE
Life of this patent
Estimating the term…
Abstract
The application describes a method of reducing emesis caused by a dopamine agonist in a patient with depression who is treated with a dopamine agonist, comprising administering ondansetron in combination with the dopamine agonist.
Claims30
A method for treating a patient suffering from major depressive disorder (MDD), comprising orally administering a pharmaceutical composition to the patient, wherein the pharmaceutical composition comprises 2 mg to 32 mg of ondansetron, or a pharmaceutically acceptable salt or solvate thereof, 0.125 mg to 20 mg of pramipexole, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
An oral tablet comprising 2 mg to 32 mg of ondansetron or a pharmaceutically acceptable salt or solvate thereof, 0.125 mg to 20 mg of pramipexole or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical carrier.
Dependencies are inferred from the claim text.